FAQ/Help |
Calendar |
Search |
Today's Posts |
08-26-2018, 02:15 AM | #6 | ||
|
|||
Member
|
From the conclusion:
"Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression." I had a lot of trouble understanding this sentence, and I found the PNT article to be of no help in that regard. Assuming I've understood it correctly, here is an alternative wording that might (or might not!) be clearer: "The dose-dependent decrease in oligomeric alpha-synuclein levels (and increase in HVA/DOPAC levels) suggests that (to potentially halt PD progression) the stage-of-disease may dictate the appropriate dose of nilotinib to administer." Anyway, it seems to me that there is still a lot of research to be done to establish the correct dose for each stage of the disease. This might well affect the prospects for a fast-track approval. Hopefully, another write-up will appear (from AlzForum, SoPD blog, ...) and shed some more light. |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Gocovri Improves Dyskinesia in Parkinson’s Patients Over Long Term, Phase 3 Trial | Parkinson's Disease | |||
MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment | Parkinson's Disease | |||
Phase 2 Trial Testing Leukemia Treatment, Nilotinib | Parkinson's Disease | |||
Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Adv Parkinson’s Dise | Parkinson's Disease | |||
Recruitment has begun for the Georgetown University "PD Nilotinib" phase 2 trial | Parkinson's Disease |